303 related articles for article (PubMed ID: 33469316)
1. Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study.
Corren J; Karpefors M; Hellqvist Å; Parnes JR; Colice G
J Asthma Allergy; 2021; 14():1-11. PubMed ID: 33469316
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma with and without Nasal Polyposis: A
Emson C; Corren J; Sałapa K; Hellqvist Å; Parnes JR; Colice G
J Asthma Allergy; 2021; 14():91-99. PubMed ID: 33568920
[TBL] [Abstract][Full Text] [Related]
3. Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR).
Pavord ID; Hoyte FCL; Lindsley AW; Ambrose CS; Spahn JD; Roseti SL; Cook B; Griffiths JM; Hellqvist Å; Martin N; Llanos JP; Martin N; Colice G; Corren J
Ann Allergy Asthma Immunol; 2023 Nov; 131(5):587-597.e3. PubMed ID: 37619779
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma and Perennial Allergy.
Corren J; Ambrose CS; Sałapa K; Roseti SL; Griffiths JM; Parnes JR; Colice G
J Allergy Clin Immunol Pract; 2021 Dec; 9(12):4334-4342.e6. PubMed ID: 34358701
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials.
Corren J; Menzies-Gow A; Chupp G; Israel E; Korn S; Cook B; Ambrose CS; Hellqvist Å; Roseti SL; Molfino NA; Llanos JP; Martin N; Bowen K; Griffiths JM; Parnes JR; Colice G
Am J Respir Crit Care Med; 2023 Jul; 208(1):13-24. PubMed ID: 37015033
[No Abstract] [Full Text] [Related]
6. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial.
Diver S; Khalfaoui L; Emson C; Wenzel SE; Menzies-Gow A; Wechsler ME; Johnston J; Molfino N; Parnes JR; Megally A; Colice G; Brightling CE;
Lancet Respir Med; 2021 Nov; 9(11):1299-1312. PubMed ID: 34256031
[TBL] [Abstract][Full Text] [Related]
7. NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma.
Menzies-Gow A; Colice G; Griffiths JM; Almqvist G; Ponnarambil S; Kaur P; Ruberto G; Bowen K; Hellqvist Å; Mo M; Garcia Gil E
Respir Res; 2020 Oct; 21(1):266. PubMed ID: 33050934
[TBL] [Abstract][Full Text] [Related]
8. Baseline type 2 biomarker levels and response to tezepelumab in severe asthma.
Corren J; Pham TH; Garcia Gil E; Sałapa K; Ren P; Parnes JR; Colice G; Griffiths JM
Allergy; 2022 Jun; 77(6):1786-1796. PubMed ID: 34913186
[TBL] [Abstract][Full Text] [Related]
9. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?
Menzies-Gow A; Wechsler ME; Brightling CE
Respir Res; 2020 Oct; 21(1):268. PubMed ID: 33059715
[TBL] [Abstract][Full Text] [Related]
10. Tezepelumab in Adults with Uncontrolled Asthma.
Corren J; Parnes JR; Wang L; Mo M; Roseti SL; Griffiths JM; van der Merwe R
N Engl J Med; 2017 Sep; 377(10):936-946. PubMed ID: 28877011
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study.
Carr TF; Moore WC; Kraft M; Brusselle G; Castro M; Chupp GL; Wechsler ME; Hunter G; Lindsley AW; Llanos JP; Burke LK; Chandarana S; Ambrose CS
Adv Ther; 2024 May; ():. PubMed ID: 38802635
[TBL] [Abstract][Full Text] [Related]
12. Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR.
Laidlaw TM; Menzies-Gow A; Caveney S; Han JK; Martin N; Israel E; Lee JK; Llanos JP; Martin N; Megally A; Parikh B; Vong S; Welte T; Corren J
J Asthma Allergy; 2023; 16():915-932. PubMed ID: 37692126
[TBL] [Abstract][Full Text] [Related]
13. SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma.
Wechsler ME; Colice G; Griffiths JM; Almqvist G; Skärby T; Piechowiak T; Kaur P; Bowen K; Hellqvist Å; Mo M; Garcia Gil E
Respir Res; 2020 Oct; 21(1):264. PubMed ID: 33050928
[TBL] [Abstract][Full Text] [Related]
14. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.
Menzies-Gow A; Corren J; Bourdin A; Chupp G; Israel E; Wechsler ME; Brightling CE; Griffiths JM; Hellqvist Å; Bowen K; Kaur P; Almqvist G; Ponnarambil S; Colice G
N Engl J Med; 2021 May; 384(19):1800-1809. PubMed ID: 33979488
[TBL] [Abstract][Full Text] [Related]
15. CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma.
Emson C; Diver S; Chachi L; Megally A; Small C; Downie J; Parnes JR; Bowen K; Colice G; Brightling CE
Respir Res; 2020 Oct; 21(1):265. PubMed ID: 33050900
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of tezepelumab in patients recruited in Japan who participated in the phase 3 NAVIGATOR study.
Ishizuka T; Menzies-Gow A; Okada H; Fukushima Y; Hayashi N; Colice G; Ponnarambil S; Hunter G; Odajima H; Ebisawa M
Allergol Int; 2023 Jan; 72(1):82-88. PubMed ID: 35977863
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study.
Menzies-Gow A; Wechsler ME; Brightling CE; Korn S; Corren J; Israel E; Chupp G; Bednarczyk A; Ponnarambil S; Caveney S; Almqvist G; Gołąbek M; Simonsson L; Lawson K; Bowen K; Colice G;
Lancet Respir Med; 2023 May; 11(5):425-438. PubMed ID: 36702146
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of tezepelumab in patients with evidence of severe allergic asthma: Results from the phase 3 NAVIGATOR study.
Corren J; Ambrose CS; Griffiths JM; Hellqvist Å; Lindsley AW; Llanos JP; Colice G; Menzies-Gow A
Clin Exp Allergy; 2023 Apr; 53(4):417-428. PubMed ID: 36507576
[TBL] [Abstract][Full Text] [Related]
19. DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma.
Menzies-Gow A; Ponnarambil S; Downie J; Bowen K; Hellqvist Å; Colice G
Respir Res; 2020 Oct; 21(1):279. PubMed ID: 33087119
[TBL] [Abstract][Full Text] [Related]
20. Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types.
Panettieri R; Lugogo N; Corren J; Ambrose CS
J Asthma Allergy; 2024; 17():219-236. PubMed ID: 38524099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
